Navigation Links
Iomai CEO to Speak at Acumen BioFin Rodman & Renshaw Annual Healthcare Conference on Monday, Nov. 5

GAITHERSBURG, Md., Nov. 2 /PRNewswire-FirstCall/ -- Iomai Corporation (Nasdaq: IOMI) today announced that Stanley C. Erck, the company's president and chief executive officer, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York City on Monday, Nov. 5. Mr. Erck's presentation will begin at 9:10 a.m. Eastern Time in the Kennedy I Room of the New York Palace Hotel.

Mr. Erck's presentation will focus on Iomai's portfolio of patch-based needle-free vaccines and immunostimulants, including its plans to move into Phase 3 trials for its travelers' diarrhea vaccine and the initiation of a Phase 1/2 trial of Iomai's dose-sparing adjuvant patch for use with a pandemic influenza vaccine.

To access the live audio webcast or the subsequent archived recording, log on to the Investor Relations section on the Overview page of the Iomai website at Please connect to Iomai's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.


Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called transcutaneous immunization (TCI). TCI, discovered by researchers at the Walter Reed Army Institute of Research, taps into the unique benefits of a major group of antigen-presenting cells found in the outer layers of the skin (Langerhans cells) to generate an enhanced immune response. Iomai is leveraging TCI to enhance the efficacy of existing vaccines, develop new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit

SOURCE Iomai Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
2. Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers Diarrhea Stimulates Immune Response Even at Low Doses
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
6. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
7. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. MaxCyte and Medinet to Present at the 13th Annual Meeting of the International Society for Cellular Therapy (ISCT) in Sydney, Australia
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):